McMahon M T, McPherson M A, Talbert R L, Greenberg B, Sheaffer S L
Clin Pharm. 1982 Jan-Feb;1(1):34-42.
The presentation, diagnosis (including provocative testing), and therapy of Prinzmetal's variant angina are reviewed. Prinzmetal's variant angina (PVA) is a form of angina caused by coronary-artery vasospasm (CAS) and is not associated with exertion. It is diagnosed by history, electrocardiogram, or coronary-artery angiography. Provocative tests, such as the cold-pressor test or intravenous ergonovine maleate, are sometimes used to aid diagnosis of PVA. Nitrates, adrenergic - blocking agents, and calcium-channel blocking agents can be used in treating PVA. Nitroglycerin and isosorbide dinitrate effectively relieve CAS. However, long-term prospective studies on the use of these drugs for PVA are lacking in the literature. Studies on treating PVA with adrenergic-blocking agents have been equivocol, with some studies reporting improvement and some reporting worsening. Calcium-channel blocking agents are promising drugs for PVA. Nifedipine is generally considered the prototype of this class for antianginal activity. It is administered orally in PVA patients and is effective. Side effects are mild and do not usually require termination of therapy. Verapamil hydrochloride, the prototype calcium-channel blocking agent for arrhythmias, is effective for PVA, but only 10-20% of an orally administered dose reaches systemic circulation because of the first-pass effect. Other calcium-channel blockers, including perhexilene maleate, diltiazem hydrochloride, prenylamine, and lidoflazine, have been tested in a few CAS patients with some success; adverse effects and toxicities limit the use of some of them, especially perhexilene. Therapy, using combinations of nitrates, adrenergic-blocking agents, and calcium-channel blocking agents, is needed in some patients. Dosing guidelines for all drugs are given in the paper. Treatment of PVA should begin with oral nitrates. Calcium-channel blocking agents are indicated in the patient who has failed to respond or is intolerant to maximum doses of nitrates given in various forms.
本文对变异型心绞痛(Prinzmetal 变异型心绞痛)的临床表现、诊断(包括激发试验)及治疗进行了综述。Prinzmetal 变异型心绞痛(PVA)是一种由冠状动脉痉挛(CAS)引起的心绞痛,与劳累无关。它通过病史、心电图或冠状动脉造影进行诊断。有时会使用激发试验,如冷加压试验或静脉注射马来酸麦角新碱,以辅助 PVA 的诊断。硝酸盐类、肾上腺素能阻滞剂和钙通道阻滞剂可用于治疗 PVA。硝酸甘油和硝酸异山梨酯能有效缓解 CAS。然而,文献中缺乏关于这些药物用于 PVA 的长期前瞻性研究。关于使用肾上腺素能阻滞剂治疗 PVA 的研究结果不一,一些研究报告病情改善,而另一些则报告病情恶化。钙通道阻滞剂是治疗 PVA 有前景的药物。硝苯地平通常被认为是此类抗心绞痛活性的原型药物。它通过口服给药用于 PVA 患者,且有效。副作用轻微,通常不需要终止治疗。盐酸维拉帕米是心律失常的原型钙通道阻滞剂,对 PVA 有效,但由于首过效应,口服剂量中只有 10 - 20%能进入体循环。其他钙通道阻滞剂,包括马来酸哌克昔林、盐酸地尔硫䓬、普尼拉明和利多氟嗪,已在少数 CAS 患者中进行了测试并取得了一定成功;不良反应和毒性限制了其中一些药物的使用,尤其是马来酸哌克昔林。一些患者需要联合使用硝酸盐类、肾上腺素能阻滞剂和钙通道阻滞剂进行治疗。本文给出了所有药物的给药指南。PVA 的治疗应从口服硝酸盐类开始。对于对各种形式的硝酸盐最大剂量无反应或不耐受的患者,应使用钙通道阻滞剂。